 The CoronaVac vaccine, also known as Sinovac, has been widely implemented in combating the COVID-19 pandemic and its effectiveness in preventing symptomatic COVID-19 was 67.7% with two doses of 3G. The review also highlights that the third dose increased effectiveness against severe COVID-19 outcomes caused by Armacron variants compared to two doses, while most adverse reactions were mild and few vaccine-related serious adverse reactions have been reported. This review may provide a scientific basis for optimizing global immunization strategies. This article was authored by Lai Runjing, Wu Peili, Xiaoying Zhong, and others.